Drugs / Stronger Neo-Minophagen C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04015245 | Apr 2018 → May 2019 | hepatocellular carcinoma | Chimei Medical Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00686881 Comparator | Dec 2006 → Feb 2011 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stronger neo minophagen C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00686881 ↗ |
| Known as | SNMC | “A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan” NCT04015245 ↗1“Comparator: Stronger neo minophagen C (SNMC)” NCT00686881 ↗ |
| Route | Intravenous | “administered at 40 mL by intravenous (IV) injection or IV infusion” NCT00686881 ↗ |